Omeros Corp

Following that repayment, our only remaining debt outstanding is $70.8 million aggregate principal amount of our 2029 Notes, which mature in June 2029.

SEC original ↗Omeros Corp — Earnings release (8-K exhibit)EX-99May 13, 2026

During the three months ended March 31, 2026, we repurchased and retired approximately 0.4 million shares of common stock pursuant to our share repurchase program, at an average cost of $11.70 per share, for an aggregate purchase price of $4.2 million.

SEC original ↗Omeros Corp — Earnings release (8-K exhibit)EX-99May 13, 2026

Significant items subject to such estimates include revenue recognition and the valuations of the OMIDRIA contract royalty asset, the OMIDRIA royalty obligation, and the embedded derivatives associated with our debt.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

We accounted for the Amendment as a modification of our existing debt from DRI.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Amortization, accretion, interest, and dividends, realized gains and losses and declines in value judged to be other-than-temporary are included within other income.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Debt The Company accounts for its convertible debt at carrying value, net of applicable discounts, premiums and debt issuance costs.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

About Omeros Corporation Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders.

SEC original ↗Omeros Corp — Earnings release (8-K exhibit)EX-99May 13, 2026

Our diverse pipeline of development programs is focused on the treatment of complement-mediated diseases, cancers, and addictive or compulsive disorders.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

We continue to progress preclinical studies within our novel oncology program, which is focused on developing novel, proprietary large molecule therapeutics designed to selectively target and kill dividing cancer cells.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Note 2 Significant Accounting Policies Segment Reporting We operate in one business segment focusing on the research, discovery, development and commercialization of small-molecule and protein therapeutics targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

The review consists of evaluating whether the business meets the definition of a component for which the operations and cash flows are clearly distinguishable from the other components of the business and, if so, whether it is anticipated that after the disposal the cash flows of the component would be eliminated from continuing operations and whether the disposition represents a strategic shift that has a major effect on operations and financial results.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

SEC original ↗Omeros Corp — Earnings release (8-K exhibit)EX-99May 13, 2026

Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks, uncertainties and other factors described in this Quarterly Report on Form 10-Q under the headings Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations and in our other filings with the U.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Given these risks, uncertainties and other factors, actual results or anticipated developments may not be realized or, even if substantially realized, may not have the expected consequences to or effects on our company, business or operations.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Legal Proceedings 22 Item 1A.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

We include such estimates in the transaction price only to the extent that it is probable that a significant reversal of revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026

Amounts are included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

SEC original ↗Omeros Corp — 10-Q Quarterly report10-QAug 12, 2026